There are currently 34 active clinical trials seeking participants for Inflammatory Bowel Diseases research studies. The states with the highest number of trials for Inflammatory Bowel Diseases participants are New York, California, Ontario and Florida.
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
Recruiting
This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of 2 active dose regimens of MORF-057 in adult study participants with moderately to severely active Crohn's disease (CD).
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
07/29/2025
Locations: Gastro Care Institute, Lancaster, California +141 locations
Conditions: Inflammatory Bowel Diseases, Crohn's Disease
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
Recruiting
This is a Phase 2, multicenter, proof-of-concept platform study in adult participants with moderately to severely active ulcerative colitis (UC). The primary goal of the study is to assess the efficacy and safety of multiple interventions following intravenous (IV) induction and subcutaneous (SC) maintenance treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2025
Locations: Site 012, Lancaster, California +10 locations
Conditions: Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis, Colitis, Ulcerative
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
Recruiting
The main purpose of this study is to evaluate the long-term efficacy of mirikizumab in pediatric participants with ulcerative colitis (UC) or Crohn's disease (CD). The study will last about 172 weeks and may include up to 44 visits. Additional treatment may be available to participants via a Continued Access Period.
Gender:
ALL
Ages:
Between 2 years and 19 years
Trial Updated:
07/22/2025
Locations: UCSF Medical Center at Mission Bay, San Francisco, California +60 locations
Conditions: Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease
Personalized Risk Estimation for Crohn's Disease (PRE-Crohn's): Implementation and Feasibility
Recruiting
The aim of this study is to develop and assess the feasibility and effect of a web-based, personalized risk-estimation for Crohn's disease (PRE-Crohn's) tool on behaviors and biomarkers associated with risk for Crohn's disease in unaffected first-degree relatives of patients with inflammatory bowel disease. We hypothesize that personalized risk disclosure via the PRE-Crohn's educational tool is both feasible and successful in modifying behaviors associated with Crohn's disease risk and normalizi... Read More
Gender:
ALL
Ages:
14 years and above
Trial Updated:
07/14/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Inflammatory Bowel Diseases, Crohn Disease, Crohn Colitis, Crohn's Ileocolitis, Crohn's Gastritis, Crohn's Jejunitis, Crohn's Duodenitis, Crohn's Esophagitis
Digital Support for Mental Health Intervention in Patients With Inflammatory Bowel Disease
Recruiting
This is a small, exploratory study that will investigate using an artificial intelligence (AI) and virtual reality (VR), digital wellness application (app) to deliver a mental health support session in outpatient and hospitalized patients with inflammatory bowel disease (IBD) and co-existing symptoms of mild to moderate anxiety or depression. The purpose of this study is to explore if a mental health support session using the app is feasible, safe, and acceptable to IBD patients and whether it... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/11/2025
Locations: University of Chicago, Chicago, Illinois
Conditions: Inflammatory Bowel Diseases, Anxiety, Depression, Ulcerative Colitis, Crohn Disease
Therapeutic Endpoint in Pediatric IBD Conditions
Recruiting
The purpose of this clinical study is the development of physiologic endpoint of inflammation in pediatric patients diagnosed with inflammatory bowel disease (IBD), specifically subtypes Crohn's disease (CD) and ulcerative colitis (UC). The novel medical device evaluates the patient's sensory response to each of the three sensory nerve fiber types. Data from the device provides an assessment of disease activity and a more precise approach to treatment.
Gender:
ALL
Ages:
Between 6 years and 21 years
Trial Updated:
07/02/2025
Locations: Children's National Health System, Washington, District of Columbia
Conditions: Inflammatory Bowel Diseases, Colitis, Ulcerative, Crohn Disease
BOOM-IBD2 Pivotal Clinical Trial
Recruiting
The BOOM-IBD2 clinical trial is designed to evaluate the effectiveness of sacral neuromodulation for the treatment of IBD.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
07/01/2025
Locations: Center for Colorectal Innovation, Los Angeles, California +9 locations
Conditions: Ulcerative Colitis, Inflammatory Bowel Diseases
Feasibility of a Wireless Thermal Capsule Endoscopy to Detect Gastrointestinal Thermal Variance
Recruiting
The goal of this research is to learn how a new device called the wireless thermal capsule (WTC) can collect thermal data to help see diseases that happen in the gastrointestinal (GI) tract, such as Crohn's Disease.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/13/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Crohn Disease, Inflammatory Bowel Diseases, Healthy
Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy
Recruiting
Randomized, placebo-controlled dose-ranging study of 2'-FL in IBD, Crohn's Disease (CD) and ulcerative colitis (UC). The overarching hypothesis is that 2'-FL supplementation in IBD will be safe and well tolerated, while increasing fecal Bifidobacterium abundance and butyrate in a dose dependent manner. The investigators will test 1, 5, or 10 gm 2'-FL compared to 2 gm dextrose placebo as a daily dietary supplement in pediatric and young adult IBD participants in stable remission receiving inflixi... Read More
Gender:
ALL
Ages:
Between 11 years and 25 years
Trial Updated:
06/11/2025
Locations: Connecticut Children's Medical Center, Hartford, Connecticut +2 locations
Conditions: Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
Regulation of Mucosal Healing in Inflammatory Bowel Disease
Recruiting
The objective of the current study is to compare non-healing colonic ulcers in patients with inflammatory bowel disease (IBD) with iatrogenic colonic ulcers (biopsy sites) in healthy control patients and patients with rheumatoid or psoriatic arthritis. Patients will be biopsied at baseline and again at a follow-up visit in a "biopsy of the biopsy" approach. These biopsies will be used to reveal patterns about gene expression and mitochondrial function during ulcer healing.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
06/04/2025
Locations: University of Kentucky, Lexington, Kentucky
Conditions: Inflammatory Bowel Diseases
A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease
Recruiting
TARGET-IBD is a 5-year, longitudinal, observational study of adult and pediatric patients (age 2 and above) being managed for Inflammatory Bowel Disease (IBD) in usual clinical practice. TARGET-IBD will create a research registry of patients with IBD within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.
Gender:
ALL
Ages:
2 years and above
Trial Updated:
06/03/2025
Locations: Om Research, Lancaster, California +36 locations
Conditions: Inflammatory Bowel Diseases, Crohn's Disease, Ulcerative Colitis, Indeterminate Colitis
Seattle Spatial Transcriptomic Research in Inflammatory Bowel Disease Evaluation (STRIDE)
Recruiting
This is a prospective observational study collecting long-term clinical data and samples for research in pediatric inflammatory bowel disease (IBD) patients with gut inflammation and a control cohort of pediatric patients with disorders of the brain-gut interactions (DBGI) with no detectable gut inflammation.
Gender:
ALL
Ages:
Between 6 years and 21 years
Trial Updated:
05/14/2025
Locations: Seattle Children's Hospital, Seattle, Washington
Conditions: Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis, Indeterminate Colitis, Functional Abdominal Pain Syndrome, Functional Bowel Disorder, Esophageal Diseases, Gastroduodenal Disorder, Bowel Dysfunction, Gallbladder Diseases, Sphincter of Oddi Dysfunction, Anorectal Disorder